 |
|
|
| |
High Sustained Virologic Response Rates in Patients with Chronic HCV GT1, 2 or 3 Infection Following 16 Weeks of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) Plus Ribavirin After Failure of 8 Weeks of Therapy (Part C of C-CREST-1 & 2)
|
| |
| |
Reported by jules Levin
AASLD 2016 Nov 11-16 Boston, MA
Lawrence Serfaty1, Stephen Pianko2, Ziv Ben Ari3, Alex L. Laursen4, Jesper Hansen5, Edward J. Gane6, Hsueh-Cheng Huang7, Shu Jin7, Jennifer Bourque7, Doreen Fernsler7, Shuyan Wan7, Frank Dutko7, Bach-Yen T. Nguyen7, Janice Wahl7, Eliav Barr7, Joan R. Butterton7
1Hopital Saint Antoine, Paris, France. 2Monash Health, Clayton, VIC, Australia. 3Sheba Medical Center, Tel Hashomer, Israel. 4Arhus Universitetshopsital, Skejby, Aarhus N, Denmark. 5Aalborg Sygehus Syd, Medicinsk Gastroenterologisk Dagafsnit, Aalborg, Denmark. 6Auckland Clinical Studies Limited, Auckland, New Zealand. 7Merck & Co., Inc., Kenilworth, NJ, USA.
|
| |
|
|
|
|
|
